Standard Article

HIV and AIDS Therapeutics

  1. Pierre R. Bonneau,
  2. Bruno Simoneau

Published Online: 15 JAN 2007

DOI: 10.1002/14356007.c13_c01.pub2

Ullmann's Encyclopedia of Industrial Chemistry

Ullmann's Encyclopedia of Industrial Chemistry

How to Cite

Bonneau, P. R. and Simoneau, B. 2007. HIV and AIDS Therapeutics. Ullmann's Encyclopedia of Industrial Chemistry. .

Author Information

  1. Boehringer Ingelheim (Canada) Ltd., Research & Development, Laval (Québec), Canada

Publication History

  1. Published Online: 15 JAN 2007

This is not the most recent version of the article. View current version (15 JAN 2007)

Abstract

The article contains sections titled:

1.Introduction – HIV and AIDS
1.1.HIV Cytopathogenesis and AIDS
1.2.Virus Life Cycle
1.3.Opportunities for Drug Intervention
2.Reverse Transcriptase Inhibitors
2.1.Introduction
2.2.Nucleoside Analogs
2.3.Nucleotide Analogs
2.4.Non-Nucleoside Analogs
2.5.Compounds in Development
3.Protease Inhibitors
3.1.Introduction
3.2.Hydroxyethylamine Isosteres
3.3.Hydroxyethylene Isosteres
3.4.Non-Peptidic Inhibitors
3.5.Compounds in Development
4.Entry Inhibitors
4.1.Introduction
4.2.Fusion Peptide
4.3.Compounds in Development
5.Emerging Concepts in AIDS Therapy
6.Acknowledgement

The human immunodeficiency virus (HIV) has been identified as the etiologic agent causing the Acquired Immuno Deficiency Syndrome (AIDS). The currently used agents for the treatment of HIV infection mainly target two important viral enzymes or inhibit viral fusion. The nucleoside analogs prematurely terminate the transcription of the viral RNA into dsDNA by reverse transcriptase. The non-nucleoside inhibitors constitute the second class of reverse transcriptase inhibitors. HIV protease, a homodimeric enzyme, is susceptible to inhibition by peptide-like structures. The process of entry of the HIV virus into the target cell can be divided into an attachment step and a fusion step. While only one inhibitor of the fusion step, Enfuvirtide, has entered the market up to now, several small-molecule inhibitors are currently in advanced development. Important efforts are being directed at the development of vaccines that can protect against HIV infection. Continued efforts are being directed at the discovery of therapies which target other essential features of the virus' life cycle, that is, the viral enzyme integrase, the viral maturation process, and the viral infectivity factor.